CoChat

Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Published version of a preprint

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Abstract New treatments for triple-negative breast cancer (TNBC) are urgently needed. Despite there being little evidence of clinical activity as single-agent therapies, we show that dual blockade of PI3Kα and CDK4/6 is synergistically effective against multiple RB1-wild-type TNBC models. Combined PI3Kα and CDK4/6 inhibition significantly increased apoptosis, cell-cycle arrest, and tumor immunogenicity and generated immunogenic cell death in human TNBC cell lines. Combination treatment also significantly improved disease control in human xenograft models compared with either monotherapy. Combined PI3Kα and CDK4/6 inhibition significantly increased tumor-infiltrating T-cell activation and cytotoxicity and decreased the frequency of immunosuppressive myeloid-derived suppressor cells in a syngeneic TNBC mouse model. Notably, combined PI3Kα and CDK4/6 inhibition, along with inhibition of immune checkpoints PD-1 and CTLA-4, induced complete and durable regressions (>1 year) of established TNBC tumors in vivo. Overall, our results illustrate convergent mechanisms of PI3Kα and CDK4/6 blockade on cell-cycle progression, DNA damage response, and immune-modulation and may provide a novel therapeutic approach for TNBC. Cancer Res; 77(22); 6340–52. ©2017 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-17-2210

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Cited by

See all 211

Metadata

Authors
Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., Phillips, W. A., Darcy, P. K., & Loi, S.
Affiliations
  • The University of Melbourne (AU)
  • Peter MacCallum Cancer Centre (AU)
Venue
Cancer Research
Published
2017-11-14
Volume
77
Issue
22
Pages
6340-6352
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2759118902
Cited by
196
References
53
Citations by year
2026: 10 · 2025: 16 · 2024: 30 · 2023: 20 · 2022: 33 · 2021: 31 · 2020: 21 · 2019: 19 · 2018: 15
FWCI
12.44
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Health and Medical Research Council (1123208, 1106967, 1041828)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
triple-negative breast cancer, CDK4/6 inhibition, PI3Kα inhibition, combination therapy, immunogenic cell death, tumor immunogenicity, tumor-infiltrating T cells, myeloid-derived suppressor cells, anti-PD-1 therapy, CTLA-4 inhibition, immune checkpoint blockade, cell cycle arrest, DNA damage response, tumor regression
MeSH terms
Aminopyridines, Animals, Antineoplastic Combined Chemotherapy Protocols, Drug Synergism, Female, Humans, Mammary Neoplasms, Experimental, Mice, Inbred C57BL, Piperazines, Purines, Pyridines, Thiazoles, Survival Analysis, Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Class I Phosphatidylinositol 3-Kinases, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-2210
The paper
Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., Phillips, W. A., Darcy, P. K., & Loi, S. (2017). Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-2210

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.